The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology - 03/01/25

Doi : 10.1016/j.jaci.2024.09.031

Aikaterini Anagnostou, MD, PhD ^a, J. Andrew Bird, MD ^b, Sharon Chinthrajah, MD ^c, Timothy E. Dribin, MD ^d, David M. Fleischer, MD ^e, Edwin Kim, MD ^f, Anna Nowak-Wegrzyn, MD, PhD ^g, Rima Rachid, MD ^h, Marcus S. Shaker, MD, MS ^i,^j, Wayne Shreffler, MD, PhD ^k, Scott Sicherer, MD ^l, Jonathan Tam, MD ^m, Brian P. Vickery, MD ⁿ, Yamini V. Virkud, MD, MA, MPH ^f, Julie Wang, MD ^l, Michael Young, MD ^h, Matthew Greenhawt, MD, MBA, MSc ^e,^⁎
^a Texas Children’s Hospital, Department of Allergy and Immunology, Houston, Tex
^b Department of Pediatrics, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex
^c Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Palo Alto, Calif
^d Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
^e Section of Allergy and Clinical Immunology, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo
^f Division of Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC
^g Department of Pediatrics, Hassenfeld Children's Hospital, New York University Grossman School of Medicine, New York, NY
^h Division of Allergy and Immunology, Boston Children's Hospital Department of Pediatrics, Harvard Medical School, Boston, Mass
ⁱ Dartmouth Hitchcock Medical Center, Section of Allergy and Clinical Immunology, Lebanon, NH
^j Geisel School of Medicine at Dartmouth, Hanover, NH
^k Division of Pediatric Allergy and Immunology and Food Allergy Center, Massachusetts General Hospital, Boston, Mass
^l Division of Allergy and Immunology, Jaffe Food Allergy Institute, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY
^m Division of Clinical Immunology and Allergy, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, Calif
ⁿ Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, Ga

^∗Corresponding author: Matthew Greenhawt, MD, MBA, MSc, Section of Allergy and Immunology, Children’s Hospital Colorado, University of Colorado School of Medicine, 13123 E. 16th Ave, Aurora, CO 80045.Section of Allergy and ImmunologyChildren’s Hospital ColoradoUniversity of Colorado School of Medicine13123 E. 16th AveAuroraCO80045

Abstract

Omalizumab was recently approved by the US Food and Drug Administration for treatment of any single food allergy or multiple food allergies in children aged 1 year and older and adults. There is currently no formal guidance regarding recommended best practices for omalizumab use in food allergy, including patient selection, anticipated goals and outcomes of therapy, procedure for monitoring patients who elect to start omalizumab therapy, and ways in which omalizumab can be incorporated into the landscape of food allergy management and daily clinical practice. This work group report was developed by the food allergy therapies subcommittee of the Adverse Reactions to Foods Committee within the American Academy of Allergy, Asthma & Immunology. Consensus, evidence-based guidance regarding experts’ recommendations for using omalizumab to treat children and adults with food allergy was developed by using modified Delphi methodology. In iterative fashion, a total of 8 statements regarding how to use omalizumab to treat patients with food allergy were developed by 16 clinical experts. This guidance provides the clinician with a suggested approach to patient selection, initiation of therapy, monitoring of efficacy, and long-term follow-up care. The role of preference-sensitive care is emphasized, with most statements offering care recommendations relevant to the culture and values of a particular practice setting.

Le texte complet de cet article est disponible en PDF.

Key words : Omalizumab, food allergy, anaphylaxis, allergen avoidance, IgE, oral food challenge, multiple food allergies

Abbreviations used : AAAAI, FDA, OFC, OIT, OUtMATCH, PDT

Plan

Methods

Results

Additional considerations

Discussion

Export

Vol 155 - N° 1

P. 62 - janvier 2025 Retour au numéro

Article précédent

Addressing health disparities in food allergy: A Position Statement of the AAAAI Prior Authorization Task Force
American Academy of Allergy, Asthma & Immunology, Aikaterini Anagnostou, Julie Wang, Sharon Chinthrajah, Ruchi Gupta, Carla M. Davis, Christopher Parrish, Rachelle Lo, Marion Groetch, Linda Herbert, Jodi Shroba, Samantha Sansweet, Marcus Shaker, Corwin Rolling, Jonathan Tam, Matthew Greenhawt

| Article suivant

Omalizumab: The journey of the first anti-IgE approved for asthma and allergic disorders
Thomas B. Casale

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology - 03/01/25

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL